TKAI


Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc and Otic Pharma Enter into Share Purchase Agreement

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) and Otic Pharma Ltd. announced that the two companies, together with the shareholders of Otic Pharma, have entered into …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Announces Review of Strategic Alternatives

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced …

William Blair Analyst Remains Sidelined on Tokai Pharmaceuticals, Inc. (TKAI) Following Q2 Update

William Blair analyst Y. Katherine Xu remains on the sidelines with shares of Tokai Pharmaceuticals, Inc.

Company Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports First Quarter 2016 Financial Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Names Kelly Lindert, M.D. its Executive Vice President and Head of Development

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports Full Year 2015 Financial Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) provided an update on its clinical development program evaluating galeterone in the treatment of men with metastatic castration-resistant prostate cancer …

Stock Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Reports Third Quarter 2015 Financial Results

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported …

Company Update (NASDAQ:TKAI): Tokai Pharmaceuticals Inc Augments Commercialization Capabilities through Appointment of Lisa Taylor as Senior Vice President, Commercial Development

Tokai Pharmaceuticals Inc (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, today announced …